Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
Launched by SIRIRAJ HOSPITAL · Aug 17, 2015
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
The subject will receive one booster dose of IMOJEV with hepatitis A vaccine (inactivated vaccine of GlaxoSmithKline) as concomitant vaccine. Blood samples will be collected to assess for Japanese Encephalitis Neutralizing Antibody at baseline (pre-vaccination) and 4 week post -vaccination.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 1 to \<5 years on the day of inclusion
- • History of received 1 dose of CD.JEVAX at 9-15 months prior to enrollment
- • In good general health at the time of inclusion
- • Provision of informed consent by the parent(s) or legal guardian(s)
- Exclusion Criteria:
- • Receipt of blood or blood products in the past 3 months
- • Acute febrile illness on the day of vaccination (Body Temperature ≥ 38 ◦C)
- • Previous receipt of 2 doses of any vaccine against JE virus
- • Known hypersensitivity to any of the vaccine components
- • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
- • Planned receipt of any live attenuated vaccine within 4 weeks following the trial vaccination
About Siriraj Hospital
Siriraj Hospital, a leading healthcare institution in Thailand, is renowned for its commitment to advancing medical research and improving patient care through clinical trials. Affiliated with Mahidol University, Siriraj Hospital integrates cutting-edge technology and innovative methodologies to conduct a wide range of clinical studies across various medical disciplines. The institution emphasizes ethical standards and patient safety, fostering collaborations with national and international research entities to contribute to the global medical community. With a focus on translating research findings into practical applications, Siriraj Hospital aims to enhance treatment options and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Kulkanya Chokephaibulkit, Professor
Principal Investigator
Siriraj Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials